Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

NCT04442581 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Terminated due to slow accrual

Conditions

Advanced Hepatocellular Carcinoma
BCLC Stage B Hepatocellular Carcinoma
BCLC Stage C Hepatocellular Carcinoma

Interventions

DRUG: Cabozantinib S-malate
BIOLOGICAL: Pembrolizumab

Sponsor

University of Washington

Collaborators

[object Object]